14
total announcements
MEDICAMEQ.NS · 15 min delayed
Key Stats · Yahoo Finance · as of 16 Oct 2026
Market Cap
₹400 Cr
P/E (TTM)
39.8
EPS (TTM)
₹7.41
52W Low
₹212.40
52W High
₹447.65
Dividend Yield
0.34%
Beta
0.69
Price / Book
1.3
Debt / Equity
17.3
Revenue (TTM)
₹206 Cr
Gross Margin
51.40%
Operating Margin
6.97%
Medicamen Biotech Limited
Medicamen Biotech Limited has informed the Exchange regarding Trading Plan pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015, disclosing a sale of 70,000 equity shares by Director Sanjay Bansal.
Medicamen Biotech Limited
Medicamen Biotech Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015. The trading window for dealing in the securities of the Company will be closed for all Designated Persons from October 01, 2026 till 48 hours after the announcement of the Financial Results for the quarter and half year ending September 30, 2026.
Medicamen Biotech Limited
Medicamen Biotech Limited held its 33rd Annual General Meeting on September 26, 2026, through video conferencing. The meeting was held in compliance with relevant regulations and circulars. The company secretary informed the members about the remote e-voting facility, the appointment of a scrutinizer, and the availability of documents for inspection. The auditor's report and the secretarial auditor's report were also discussed.
Medicamen Biotech Limited
Medicamen Biotech Limited has informed the Exchange about the publication of a newspaper advertisement for its 33rd Annual General Meeting, e-Voting, and Book Closure.
Medicamen Biotech Limited
Medicamen Biotech Limited has informed the Exchange regarding 'Submission of Integrated Annual Report for FY 2025-26 and Notice of the 33rd Annual General Meeting (AGM) of Medicamen Biotech Limited (the Company) to be held through Video Conferencing/Other Audio-Visual Means (VC/OAVM) on September 26, 2026'.
Medicamen Biotech Limited
Medicamen Biotech Limited has submitted its Business Responsibility and Sustainability Report (BRSR) for the financial year 2025-26, as per the provisions of Regulation 34(2)(f) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.
Medicamen Biotech Limited
Medicamen Biotech Limited has informed the Exchange regarding 'Intimation of Book Closure and Record Date in accordance with Regulation 42 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015'. The company's Register of Members and Share Transfer Books will be closed from 20 September 2026 to 26 September 2026 for the purpose of the 33rd Annual General Meeting and for determining the entitlement of members to receive the Final Dividend for the Financial Year 2025-26.
Medicamen Biotech Limited
Medicamen Biotech Limited has published a copy of newspaper publication regarding the un-audited financial results for the quarter ended June 30, 2026, as approved by the Board of Directors on August 14, 2026.
Medicamen Biotech Limited
Medicamen Biotech Limited has informed the Exchange regarding 'Closure of Register of Members and Share Transfer Books'.
Medicamen Biotech Limited
Medicamen Biotech Limited has set a record date for the purpose of dividend distribution as 19-Sep-2026.
Medicamen Biotech Limited
Medicamen Biotech Limited has submitted its unaudited financial results for the quarter ended June 30, 2026, and the Board of Directors has approved the results. The company has also announced the closure of the Register of Members and share transfer books, and the payment of a final dividend. The Board has taken note of notices/communications received from the stock exchanges regarding non-compliance/compliance-related matters.
Medicamen Biotech Limited
Medicamen Biotech Limited has informed the Exchange about Certificate under SEBI (Depositories and Participants) Regulations, 2018, for the quarter ended on June 30, 2026, confirming and certifying the securities dematerialized / rematerialized during the quarter.
Medicamen Biotech Limited
Medicamen Biotech Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015. The trading window will be closed for all Directors/Designated Persons/Connected Persons from July 01, 2026, and will remain closed till 48 hours after the declaration of Un-audited Financial Results for the quarter ended on June 30, 2026.
Medicamen Biotech Limited
Medicamen Biotech Limited has submitted its annual disclosure under Regulation 31(4) of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011. This filing, made by the promoter Shivalik Rasayan Limited, covers the year ended March 31, 2026. It is a routine compliance submission to the exchanges.